TORONTO--(BUSINESS WIRE)--Xagenic, a molecular diagnostics company developing the lab-free Xagenic X1™ platform, today announced that it has acquired exclusive rights to a proprietary mutation detection technology developed at the University of Toronto.
This newly-acquired technology detects specific cell-free nucleic acids (cfNA) in blood plasma or serum, potentially enabling the Xagenic X1 platform to expand into “liquid biopsy,” or blood-based testing, in lieu of invasive tissue biopsy for oncology diagnostics and other instances in which an invasive tissue biopsy is not optimal or possible.
Help employers find you! Check out all the jobs and post your resume.
